WO2011070970A1 - Inhibiteur de surexpression de lymphopoïétine stromale thymique - Google Patents

Inhibiteur de surexpression de lymphopoïétine stromale thymique Download PDF

Info

Publication number
WO2011070970A1
WO2011070970A1 PCT/JP2010/071595 JP2010071595W WO2011070970A1 WO 2011070970 A1 WO2011070970 A1 WO 2011070970A1 JP 2010071595 W JP2010071595 W JP 2010071595W WO 2011070970 A1 WO2011070970 A1 WO 2011070970A1
Authority
WO
WIPO (PCT)
Prior art keywords
tslp
fraction
water
hop
overexpression
Prior art date
Application number
PCT/JP2010/071595
Other languages
English (en)
Japanese (ja)
Inventor
典均 澤田
隆 小島
潤 渕本
直之 小林
Original Assignee
北海道公立大学法人札幌医科大学
サッポロビール株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 北海道公立大学法人札幌医科大学, サッポロビール株式会社 filed Critical 北海道公立大学法人札幌医科大学
Priority to JP2011545188A priority Critical patent/JPWO2011070970A1/ja
Publication of WO2011070970A1 publication Critical patent/WO2011070970A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a thymic stromal lymphopoietin (TSLP) overexpression inhibitor.
  • TSLP thymic stromal lymphopoietin
  • Th1 cells and Th2 cells control the immune response while maintaining a balance.
  • Th2 cell predominates the production of IgE antibody is promoted by the entry of a foreign substance (antigen), and allergic symptoms such as bronchial asthma and allergic dermatitis are caused.
  • TSLP has attracted attention regarding the onset mechanism of such allergic diseases.
  • TSLP is a cytokine that is secreted from epithelial cells of the respiratory tract and skin and induces Th2-type T cell differentiation, and has been shown to be involved in allergic reactions through creating a state predominantly Th2 cells.
  • Suppressing the action of TSLP is considered effective for the prevention and treatment of TSLP-dependent diseases including allergic diseases.
  • substances that suppress the action of TSLP for example, anti-TSLP antibodies and anti-TSLP receptor antibodies are known (see Patent Documents 1 and 2).
  • An object of the present invention is to provide a novel TSLP overexpression inhibitor.
  • the present invention provides a TSLP overexpression inhibitor containing a hop water extract as an active ingredient.
  • hop water extract refers to an extract of hop tissue with water of 0 to 50 ° C. (excluding 0 ° C.).
  • TSLP overexpression means that TSLP (protein) or a gene product (for example, mRNA) generated in the production process thereof exceeds the normal level.
  • the present invention is also a TSLP overexpression inhibitor containing a water-soluble fraction of hop water extract as an active ingredient, wherein the water-soluble fraction is obtained by partitioning the hop water extract with water and a hydrophobic organic solvent.
  • a TSLP overexpression inhibitor which is a fraction separated on the aqueous layer side, is provided.
  • the present invention is also a TSLP overexpression inhibitor containing, as an active ingredient, a high molecular fraction obtained from a water-soluble fraction of hop water extract, wherein the water-soluble fraction is water-hydrophobic and hydrophobic. This fraction is separated to the aqueous layer side when distributed with an organic solvent, and the polymer fraction is a fraction of a substance that does not permeate the ultrafiltration membrane with a fractional molecular weight of about 1000 to about 3000.
  • An expression inhibitor is provided.
  • the present invention is also a TSLP overexpression inhibitor containing, as an active ingredient, a high molecular weight polyphenol fraction obtained from a water-soluble fraction of hop water extract, wherein the water-soluble fraction contains hop water extract and water and hydrophobic.
  • the polymer polyphenol fraction is a fraction of polyphenol that does not permeate an ultrafiltration membrane having a molecular weight cut off of about 1000 to about 3000 when it is separated with an organic solvent.
  • the “hydrophobic organic solvent” refers to an organic solvent that is not mixed with water at an arbitrary ratio.
  • the word “about” added before the numerical value indicating the molecular weight cut off represents a range of ⁇ 10% of the numerical value. For example, “about 1000” means 900 to 1100, and “about 3000” means 2700 to 3300.
  • the TSLP overexpression inhibitor of the present invention is a TSLP-dependent disease (a disease that develops by involving TSLP) through suppression of TSLP overexpression (for example, bronchial asthma, allergic dermatitis, allergic rhinitis, hay fever, food, Allergy, fibrosis, inflammatory bowel disease, Hodgkin lymphoma) can be prevented or treated.
  • a TSLP-dependent disease a disease that develops by involving TSLP
  • suppression of TSLP overexpression for example, bronchial asthma, allergic dermatitis, allergic rhinitis, hay fever, food, Allergy, fibrosis, inflammatory bowel disease, Hodgkin lymphoma
  • TSLP-dependent disease a disease that develops by involving TSLP
  • suppression of TSLP overexpression for example, bronchial asthma, allergic dermatitis, allergic rhinitis, hay fever, food, Allergy, fibrosis, inflammatory
  • Hop is a plant that has been used for various purposes including beer brewing for a long time, and safety for living organisms has been established. Therefore, the TSLP overexpression inhibitor of the present invention is highly safe to the living body and can be ingested daily and continuously, and not only as a pharmaceutical ingredient, but also a food and drink, a food and drink additive, a feed and a feed addition It is also suitable as a material for things.
  • a novel TSLP overexpression inhibitor and a pharmaceutical, a food, a food, a food additive, a feed, a feed additive and the like containing the same are provided.
  • the present invention provides a TSLP overexpression inhibitor containing a hop water extract as an active ingredient.
  • hop water extract refers to an extract of hop tissue with water at 0 to 50 ° C. (excluding 0 ° C.).
  • the hop tissue used for water extraction is not particularly limited, and may be, for example, spikelets, camellias, stems, or leaves.
  • the hop structure may be subjected to treatments such as drying, freezing, processing, pulverization, and selection, and for example, hop pellets may be used.
  • the hop structure is preferably dried at a temperature of 55 ° C. or less until the water content becomes 10% by weight or less, for example.
  • the method for freezing the hop tissue is not particularly limited, but the freezing temperature is preferably ⁇ 10 ° C. or lower, and particularly preferably ⁇ 35 ° C. or lower.
  • the hop structure can be pulverized using, for example, a pulverizer such as a pin mill, a hammer mill, or a ball mill.
  • the hop tissue may be passed through a sieve having a certain size (for example, 0.1 mm, 0.3 mm, 0.5 mm).
  • the hop varieties are not particularly limited, and may be any of existing varieties (for example, Czech Saats species, German Haratau Magnum species, German Haratau tradition species, German Perrelet species). One kind may be used alone, or two or more kinds may be used in combination.
  • the temperature of water used for water extraction may be 0 to 50 ° C. (excluding 0 ° C.), preferably 1 to 40 ° C., more preferably 1 to 30 ° C.
  • the water extraction of the hop tissue can be performed according to a conventional method.
  • a hop structure and water are put in a container and left to stand for a predetermined time with appropriate stirring.
  • the liquid obtained by standing can be used as it is as a water extract solution.
  • a supernatant obtained by centrifuging such a liquid can be used as a solution of an aqueous extract. If such a liquid or supernatant is concentrated and dried, a water extract is obtained.
  • Water extraction may be performed by adding a small amount (10 wt% or less) of alcohol (preferably ethanol) to water in order to increase extraction efficiency and shorten extraction time.
  • hop water extract it may be used.
  • Another aspect of the present invention is a TSLP overexpression inhibitor containing a water-soluble fraction of a hop water extract as an active ingredient, wherein the water-soluble fraction is a combination of water and a hydrophobic organic substance.
  • a TSLP overexpression inhibitor which is a fraction separated on the aqueous layer side when distributed with a solvent, is provided.
  • hydrophobic organic solvent refers to an organic solvent that is not mixed with water at an arbitrary ratio.
  • examples of such a solvent include hexane, ethyl acetate, n-butanol, diethyl ether, and chloroform.
  • the water-soluble fraction may be a fraction that is separated into an aqueous layer by performing a single dispensing operation, or may be further subjected to one or more dispensing operations for the aqueous layer obtained first. It may be a fraction that is newly separated into the aqueous layer by performing the above.
  • a step of adding hexane to an aqueous solution of hop water extract to perform liquid-liquid partition a step of adding ethyl acetate to the aqueous layer obtained in step (a) to perform liquid-liquid partition
  • a water-soluble fraction can be obtained by concentrating and drying the aqueous layer obtained by one or more liquid-liquid distributions.
  • the present invention in a further aspect, is a TSLP overexpression inhibitor containing a polymer fraction obtained from the water-soluble fraction as an active ingredient, wherein the polymer fraction has a molecular weight cut-off of about 1000 to about 3000.
  • a TSLP overexpression inhibitor which is a fraction of a substance that does not permeate the ultrafiltration membrane.
  • the present invention in a further aspect, is a TSLP overexpression inhibitor containing a high-molecular polyphenol fraction obtained from the water-soluble fraction as an active ingredient, wherein the high-molecular polyphenol fraction has a molecular weight cut-off of about
  • the present invention provides a TSLP overexpression inhibitor, which is a polyphenol fraction that does not permeate 1000 to about 3000 ultrafiltration membranes.
  • the polymer fraction is obtained, for example, by filtering the solution of the water-soluble fraction with an ultrafiltration membrane having a molecular weight cut off of about 1000 to about 3000, and collecting and drying the material that has not permeated the membrane. Can do. Alternatively, by first filtering the hop water extract solution through an ultrafiltration membrane, then partitioning the membrane-impermeable fraction with water and a hydrophobic organic solvent, and concentrating and drying the resulting aqueous layer. Can also be obtained.
  • the polymer polyphenol fraction can be obtained, for example, by bringing the polymer fraction solution into contact with an adsorbent that selectively adsorbs polyphenol, and then separating the adsorbed material from the adsorbent.
  • the solution of the water-soluble fraction is brought into contact with an adsorbent, then the adsorbed substance is separated from the adsorbent, and this is further fractionated with an ultrafiltration membrane having a fractional molecular weight of about 1000 to about 3000.
  • the hop water extract solution is first brought into contact with the adsorbent, then the adsorbed material is separated from the adsorbent, and liquid-liquid distribution and ultrafiltration are performed in any order on the adsorbent.
  • PVPP polyvinyl polypyrrolidone
  • styrene-divinylbenzene adsorbent hydrophilic vinyl polymer adsorbent
  • methacrylate ester adsorbent examples include polyvinyl polypyrrolidone (PVPP), styrene-divinylbenzene adsorbent, hydrophilic vinyl polymer adsorbent, and methacrylate ester adsorbent.
  • the molecular weight cut off of the ultrafiltration membrane may be about 1000 to about 3000.
  • about 1500 to about 3000 is more preferable in that a higher TSLP overexpression inhibitory effect can be obtained.
  • 2000 to about 3000 is more preferred, about 2500 to about 3000 is more preferred, and about 3000 is particularly preferred.
  • the TSLP overexpression inhibitor of the present invention may further contain other components having a TSLP overexpression inhibitory action.
  • the TSLP overexpression inhibitor of the present invention may be composed of a hop water extract or a water-soluble fraction thereof, a water-soluble polymer fraction or a water-soluble polymer polyphenol fraction. Further, it may essentially consist of a hop water extract or a water-soluble fraction thereof, a water-soluble polymer fraction or a water-soluble polymer polyphenol fraction.
  • the TSLP overexpression inhibitor of the present invention may be in any form of a solid (for example, a powder obtained by lyophilization), a liquid (solution or suspension), a paste, etc., and powders, granules, tablets, Any dosage form such as capsules, solutions, suspensions, emulsions, ointments, plasters and the like may be used.
  • the above-mentioned various preparations include a hop water extract or a water-soluble fraction thereof, a water-soluble polymer fraction or a water-soluble polymer polyphenol fraction, and pharmaceutically acceptable additives (excipients, binders, lubricants). And a dispersant, a disintegrant, an emulsifier, a surfactant, a base, a solubilizing agent, a suspending agent, and the like).
  • examples of the excipient include lactose, sucrose, starch, dextrin and the like.
  • the binder include polyvinyl alcohol, gum arabic, tragacanth, gelatin, hydroxypropylmethylcellulose, hydroxypropylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone and the like.
  • examples of the lubricant include magnesium stearate, calcium stearate, talc and the like.
  • examples of the disintegrant include crystalline cellulose, agar, gelatin, calcium carbonate, sodium bicarbonate, dextrin and the like.
  • the emulsifier or surfactant include Tween 60, Tween 80, Span 80, and glyceryl monostearate.
  • Examples of the base include cetostearyl alcohol, lanolin, polyethylene glycol, rice bran oil, fish oil (DHA, EPA, etc.), olive oil and the like.
  • Examples of the solubilizer include polyethylene glycol, propylene glycol, sodium carbonate, sodium citrate, Tween 80 and the like.
  • Examples of the suspending agent include Tween 60, Tween 80, Span 80, glyceryl monostearate, polyvinyl alcohol, polyvinyl pyrrolidone, methyl cellulose, hydroxymethyl cellulose, sodium alginate and the like.
  • the TSLP overexpression inhibitor of the present invention can be used as a component of pharmaceuticals, foods and drinks (beverages, foods), food and drink additives, feeds, feed additives, and the like.
  • examples of the beverage include water, soft drinks, fruit juice beverages, milk beverages, alcoholic beverages, sports drinks, and nutritional drinks.
  • foods include breads, noodles, rice, tofu, dairy products, soy sauce, miso, and confectionery.
  • the TSLP overexpression inhibitor of the present invention can also be used as a component for food for specified health use, food for special use, dietary supplement, health food, functional food, food for patients and the like.
  • Beverages, foods, feeds, etc. may further contain additives usually used in the field.
  • additives include bitters, flavors, apple fiber, soybean fiber, meat extract, black vinegar extract, gelatin, corn starch, honey, animal and vegetable oils and fats; proteins such as gluten; beans such as soybeans and peas; glucose Monosaccharides such as fructose; disaccharides such as sucrose; polysaccharides such as dextrose and starch; sugar alcohols such as erythritol, xylitol, sorbitol and mannitol; vitamins such as vitamin C; minerals such as zinc, copper and magnesium Functional materials such as CoQ10, ⁇ -lipoic acid, carnitine, capsaicin; These additives may be used alone or in combination of two or more.
  • the TSLP overexpression inhibitor of the present invention may be ingested by humans or non-human mammals.
  • the intake amount and the intake method can be appropriately determined according to the state, age, etc. of the individual.
  • a suitable intake method for example, oral intake can be mentioned.
  • Example 1 Preparation of test sample 1 kg of hop pellets (Czech zatz species: type 90) was placed in 10 L of distilled water (5 ° C.) and stirred occasionally at 5 ° C., and allowed to stand overnight while the pellet state disappeared. After centrifuging at 7000 rpm for 15 minutes, the supernatant was recovered and further concentrated and dried to obtain 150 g of hop water extract. A part of the sample was diluted with distilled water to obtain a test sample having a predetermined concentration.
  • the precipitate containing the nasal mucosal epithelial cells was added to BEBM medium (Lonza) [0.5 ⁇ g / mL hydrocortisone, 5 ⁇ g / mL insulin, 10 ⁇ g / mL transferrin, 0.5 ⁇ g / mL epinephrine, 6.5 ⁇ g / mL triiodo silo.
  • a retroviral vector (BABE-hygro-hTERT) was used to introduce the hTERT gene into nasal mucosal epithelial cells (specifically, retrovirus producing cells (A293 cells)). The culture supernatant was added to nasal mucosal epithelial cells and incubated for 24 hours).
  • nasal mucosal epithelial cells were seeded in a 12-well plate with a medium and incubated in a CO 2 incubator (37 ° C., 5% CO 2 ) for 5-7 days. Then, the medium was replaced with a BEBM medium (Lonza) supplemented with 25 ⁇ g / mL poly I: C (polyinosine-polycytic acid), and incubated for 24 hours with or without the addition of a predetermined amount of test sample (one sample). In some wells, the medium was replaced with medium without poly I: C and incubated without the addition of the test sample).
  • Poly I: C is a substance that induces TSLP expression.
  • TSLP expression level (TSLP production level and TSLP mRNA production level) was measured.
  • TSLP concentration pg / mL
  • FIG. 1 is a graph showing the amount of TSLP produced in human nasal mucosal epithelial cells.
  • FIG. 2 is a graph showing the amount of TSLP mRNA produced in human nasal mucosal epithelial cells.
  • “HWE” represents a hop water extract.
  • the poly I C concentration ( ⁇ g / mL) and the hop water extract concentration (ppm) both indicate the concentration in the medium.
  • the amount of TSLP produced is indicated by the TSLP concentration (pg / mL) in the culture supernatant.
  • the TSLP mRNA production amount is shown by the ratio of TSLP mRNA amount to 18S rRNA amount.
  • Example 1 confirmed that the hop water extract has a TSLP overexpression inhibitory action.
  • Example 2 Preparation of test sample 250 g of hop pellets (SSA-pellets) were placed in 3 L of distilled water, stirred, and allowed to stand overnight in a low temperature chamber (25 ° C.). After centrifugation at 8000 rpm and 4 ° C. for 20 minutes, the supernatant was collected. Filtered on 2. The filtrate was concentrated to 600 mL to obtain an aqueous solution of hop water extract.
  • SSA-pellets hop pellets
  • the obtained aqueous layer was further subjected to liquid-liquid distribution with 150 mL of ethyl acetate (twice).
  • An emulsion layer was formed between the ethyl acetate layer (upper layer) and the aqueous layer (lower layer), and this was further centrifuged (3000 rpm, 20 ° C., 10 minutes).
  • the obtained ethyl acetate layer was concentrated and dried to obtain an ethyl acetate layer fraction (786.1 mg). A part of the sample was diluted with distilled water to obtain a test sample having a predetermined concentration.
  • liquid-liquid distribution was further performed with 150 mL of n-butanol (3 times).
  • An emulsion layer was formed between the butanol layer (upper layer) and the aqueous layer (lower layer), and this was further centrifuged (3000 rpm, 20 ° C., 10 minutes).
  • the resulting butanol layer and aqueous layer were concentrated and dried to obtain a butanol layer fraction (1.0 g) and an aqueous layer fraction (45.32 g). A part of each fraction was diluted with distilled water to obtain a test sample having a predetermined concentration.
  • Human nasal mucosal epithelial cells were cultured in the same manner as in Example 1.
  • TSLP expression was induced in the same manner as in Example 1.
  • TSLP expression level After inducing TSLP expression, the TSLP expression level (TSLP production level) was measured. The amount of TSLP produced was measured in the same manner as in Example 1.
  • FIG. 3 is a graph showing the amount of TSLP produced in human nasal mucosal epithelial cells.
  • control represents the case where no test sample was added.
  • the poly I C concentration ( ⁇ g / mL) and the fraction concentration ( ⁇ g / mL) both indicate the concentration in the medium.
  • the amount of TSLP produced is indicated by the TSLP concentration (pg / mL) in the culture supernatant.
  • Example 2 confirmed that the water-soluble fraction of the hop water extract has a TSLP overexpression inhibitory action.
  • Example 3 (Preparation of test sample) 50 mg of the aqueous layer fraction obtained in Example 2 was dissolved in 5 mL of distilled water, and this solution was centrifuged at 3000 rpm at 20 ° C. for 3 hours using an ultrafiltration membrane (Amicon Ultra) having a fractional molecular weight of 3000. Filtration was performed.
  • the substance that did not permeate the ultrafiltration membrane was collected and dried to obtain a polymer fraction.
  • the filtrate was concentrated and dried to obtain a low molecular fraction.
  • a part of each fraction was diluted with distilled water to obtain a test sample having a predetermined concentration.
  • Human nasal mucosal epithelial cells were cultured in the same manner as in Example 1.
  • TSLP expression was induced in the same manner as in Example 1.
  • FIG. 4 is a graph showing the amount of TSLP produced in human nasal mucosal epithelial cells.
  • control represents the case where no test sample was added.
  • the poly I C concentration ( ⁇ g / mL) and the fraction concentration ( ⁇ g / mL) both indicate the concentration in the medium.
  • the amount of TSLP produced is indicated by the TSLP concentration (pg / mL) in the culture supernatant.
  • Example 3 confirms that the water-soluble polymer fraction of the hop water extract has a TSLP overexpression inhibitory action.
  • Example 4 (Preparation of test sample) First, 2.5 g of polyvinylpolypyrrolidone (PVPP) powder was added to 50 mL of distilled water and stirred for 1 hour to obtain a PVPP slurry. Next, 37.5 mg of the polymer fraction obtained in Example 3 was dissolved in 15 mL of distilled water, and the PVPP slurry was added to this solution and gently stirred for 30 minutes. Finally, the mixture was filtered to collect PVPP, and the PVPP adsorbed fraction was eluted with 5% NH 3 / CH 3 OH.
  • PVPP polyvinylpolypyrrolidone
  • the obtained eluate was used as a test sample for the PVPP adsorption fraction in a TSLP expression induction experiment (described later).
  • the filtrate was used as it was as a test sample for the PVPP non-adsorbed fraction.
  • Human nasal mucosal epithelial cells were cultured in the same manner as in Example 1.
  • TSLP expression was induced in the same manner as in Example 1.
  • FIG. 5 is a graph showing the amount of TSLP produced in human nasal mucosal epithelial cells.
  • control represents a case where no test sample was added.
  • the poly I C concentration ( ⁇ g / mL) indicates the concentration in the medium.
  • the TSLP production amount is shown as the TSLP concentration (pg / mL) in the culture supernatant.
  • PVPP is an adsorbent that selectively adsorbs polyphenols.
  • Example 4 confirms that the water-soluble polymer polyphenol fraction of the hop water extract has a TSLP overexpression inhibitory action.
  • the TSLP overexpression inhibitor of the present invention is useful for the prevention and treatment of TSLP-dependent diseases including allergic diseases.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Otolaryngology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne un inhibiteur de surexpression de lymphopoïétine stromale thymique (TSLP) qui contient, en tant que substance active, un extrait aqueux de houblon, une fraction hydrosoluble de celui-ci, une fraction de polymère hydrosoluble de celui-ci ou une fraction de polyphénol polymère hydrosoluble de celui-ci. L'inhibiteur de surexpression de TSLP ci-dessus permet la prévention et/ou le traitement fondamentaux de maladies allergiques et l'amélioration d'une prédisposition allergique. Cet inhibiteur de surexpression de TSLP peut être pris chaque jour et en continu et est utilisable non seulement en tant que composant de médicaments mais également en tant que matériau de départ d'aliments, de boissons, etc.
PCT/JP2010/071595 2009-12-07 2010-12-02 Inhibiteur de surexpression de lymphopoïétine stromale thymique WO2011070970A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2011545188A JPWO2011070970A1 (ja) 2009-12-07 2010-12-02 胸腺間質性リンパ球新生因子過剰発現抑制剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009277906 2009-12-07
JP2009-277906 2009-12-07

Publications (1)

Publication Number Publication Date
WO2011070970A1 true WO2011070970A1 (fr) 2011-06-16

Family

ID=44145515

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2010/071595 WO2011070970A1 (fr) 2009-12-07 2010-12-02 Inhibiteur de surexpression de lymphopoïétine stromale thymique

Country Status (2)

Country Link
JP (1) JPWO2011070970A1 (fr)
WO (1) WO2011070970A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014117239A (ja) * 2012-12-18 2014-06-30 Sapporo Breweries Ltd Ｔｒｐｖ１刺激剤及びその製造方法
JP2017018089A (ja) * 2015-07-14 2017-01-26 株式会社東洋新薬 ホップ葉含有飲食用組成物
US10000561B2 (en) 2015-09-09 2018-06-19 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
WO2020137975A1 (fr) * 2018-12-27 2020-07-02 サントリーホールディングス株式会社 Procédé de fabrication d'une composition contenant du xanthohumol
US10745473B2 (en) 2015-09-09 2020-08-18 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001278792A (ja) * 2000-03-28 2001-10-10 Kikkoman Corp 抗アレルギー、抗炎症剤並びにこれを含有する医薬組成物、医薬部外品、化粧品、食品及び動物用飼料
JP2005082497A (ja) * 2003-09-05 2005-03-31 Asahi Breweries Ltd 植物由来ポリフェノール成分を有効成分として含むことを特徴とする免疫調節剤
JP2006096694A (ja) * 2004-09-29 2006-04-13 Asahi Breweries Ltd 食物アレルギー予防剤
WO2006093194A1 (fr) * 2005-03-03 2006-09-08 Sapporo Breweries Limited Composition antiallergique
WO2006115123A1 (fr) * 2005-04-19 2006-11-02 Asahi Breweries, Ltd. Agent d'inactivation virale
WO2008026473A1 (fr) * 2006-08-31 2008-03-06 Asahi Breweries, Ltd. Procede de production d'une preparation a base de houblon, preparation a base de houblon ainsi obtenue, agent anti-inflammatoire, aliment/boisson et produit pharmaceutique par voie orale
JP2008273860A (ja) * 2007-04-26 2008-11-13 Oita Univ 柚子果皮に由来するＮＦ−κＢ／Ｔｈ２亢進抑制剤およびその用途
WO2009093533A1 (fr) * 2008-01-24 2009-07-30 Sapporo Breweries Limited INHIBITEUR DE LA PRODUCTION D'ANTICORPS IgE

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001278792A (ja) * 2000-03-28 2001-10-10 Kikkoman Corp 抗アレルギー、抗炎症剤並びにこれを含有する医薬組成物、医薬部外品、化粧品、食品及び動物用飼料
JP2005082497A (ja) * 2003-09-05 2005-03-31 Asahi Breweries Ltd 植物由来ポリフェノール成分を有効成分として含むことを特徴とする免疫調節剤
JP2006096694A (ja) * 2004-09-29 2006-04-13 Asahi Breweries Ltd 食物アレルギー予防剤
WO2006093194A1 (fr) * 2005-03-03 2006-09-08 Sapporo Breweries Limited Composition antiallergique
WO2006115123A1 (fr) * 2005-04-19 2006-11-02 Asahi Breweries, Ltd. Agent d'inactivation virale
WO2008026473A1 (fr) * 2006-08-31 2008-03-06 Asahi Breweries, Ltd. Procede de production d'une preparation a base de houblon, preparation a base de houblon ainsi obtenue, agent anti-inflammatoire, aliment/boisson et produit pharmaceutique par voie orale
JP2008273860A (ja) * 2007-04-26 2008-11-13 Oita Univ 柚子果皮に由来するＮＦ−κＢ／Ｔｈ２亢進抑制剤およびその用途
WO2009093533A1 (fr) * 2008-01-24 2009-07-30 Sapporo Breweries Limited INHIBITEUR DE LA PRODUCTION D'ANTICORPS IgE

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AL-SHAMI A. ET AL: "A role for TSLP in the development of inflammation in an asthma model", J EXP MED., vol. 202, no. 6, 19 September 2005 (2005-09-19), pages 829 - 839, XP002528757, DOI: doi:10.1084/jem.20050199 *
HIRASAWA N ET AL.: "Analysis of the mechanism for the development of allergic skin inflammation and the application for its treatment: establishment of a modified allergic dermatitis model in mouse ear lobes by application of 12-O-tetradecanoyl phorbol 13-acetate: putative involvement of thymic stromal lymphopoietin ..", J PHARMACOL SCI., vol. 110, no. 3, July 2009 (2009-07-01), pages 245 - 250 *
SEGAWA SHUICHI ET AL.: "Clinical Effects of a Hop Water Extract on Japanese Cedar Pollinosis during the Pollen Season: A Double-Blind, Placebo-Controlled Trial", BIOSCI BIOTECHNOL BIOCHEM, vol. 71, no. 8, August 2007 (2007-08-01), pages 1955 - 1962 *
SEGAWA SHUICHI ET AL.: "Effects of a Hop Water Extract on the Compound 48/80-Stimulated Vascular Permeability in ICR Mice and Histamine Release from OVA-Sensitized BALB/c Mice", BIOSCI BIOTECHNOL BIOCHEM, vol. 71, no. 6, June 2007 (2007-06-01), pages 1577 - 1581 *
SEGAWA SHUICHI ET AL.: "Flavonoid Glycosides Extracted from Hop (Humulus lupulus L.) as Inhibitors of Chemical Mediator Release from Human Basophilic KU812 Cells", BIOSCI BIOTECHNOL BIOCHEM, vol. 70, no. 12, December 2006 (2006-12-01), pages 2990 - 2997, XP055009369, DOI: doi:10.1271/bbb.60384 *
SEGAWA SHUICHI ET AL.: "Oral Administration of a Hop Water Extract Ameliorates the Development of Dermatitis Induced by the Periodical Topical Application of a Mite Antigen in Atopic Dermatitis Model NC/Nga Mice", BIOSCI BIOTECHNOL BIOCHEM, vol. 72, no. 4, April 2008 (2008-04-01), pages 974 - 981 *
TAKASHI KANEKO: "Kinosei Shokuhin Sozai no Kinkyo, Mizu Chushutsu Hop Polyphenol no Kinosei ni Tsuite", JAPAN FOOD SCIENCE, vol. 47, no. 1, 5 January 2008 (2008-01-05), pages 48 - 53 *
TAKUBO MIHO ET AL.: "Effects of Hop Extracts on Nasal Rubbing and Sneezing in BALB/c Mice", BIOL PHARM BULL, vol. 29, no. 4, April 2006 (2006-04-01), pages 689 - 692 *
YOO J ET AL.: "Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin", J EXP MED., vol. 202, no. 4, 15 August 2005 (2005-08-15), pages 541 - 549 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014117239A (ja) * 2012-12-18 2014-06-30 Sapporo Breweries Ltd Ｔｒｐｖ１刺激剤及びその製造方法
JP2017018089A (ja) * 2015-07-14 2017-01-26 株式会社東洋新薬 ホップ葉含有飲食用組成物
US10000561B2 (en) 2015-09-09 2018-06-19 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
US10745473B2 (en) 2015-09-09 2020-08-18 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
WO2020137975A1 (fr) * 2018-12-27 2020-07-02 サントリーホールディングス株式会社 Procédé de fabrication d'une composition contenant du xanthohumol
JPWO2020137975A1 (ja) * 2018-12-27 2021-10-14 サントリーホールディングス株式会社 キサントフモールを含有する組成物の製造方法
JP7234260B2 (ja) 2018-12-27 2023-03-07 サントリーホールディングス株式会社 キサントフモールを含有する組成物の製造方法

Also Published As

Publication number Publication date
JPWO2011070970A1 (ja) 2013-04-22

Similar Documents

Publication Publication Date Title
KR100842053B1 (ko) 계피 추출물을 유효성분으로 함유하는 장내 균총 개선 및면역기능 증진용 조성물
KR20110082481A (ko) 발효식품에서 유래된 세포밖 소포체를 포함하는 조성물 및 이의 용도
WO2010150867A1 (fr) Produit fermenté d'un matériau dérivé d'une céréale et immunomodulateur
TWI740030B (zh) 包含植物萃取物的組成物及其於促進ｇｌｕｔ４基因表現之用途
JP2010209051A (ja) 脂肪吸収抑制剤
WO2011070970A1 (fr) Inhibiteur de surexpression de lymphopoïétine stromale thymique
JP7395622B2 (ja) 新規なフィーカリバクテリウムプラウスニッツィイ菌株ｅｂ－ｆｐｄｋ１１およびその用途
JP2008214215A (ja) アポトーシス誘導能を有する組成物
JP5203393B2 (ja) アルコール性肝障害抑制剤
JPWO2016204120A1 (ja) 竹発酵抽出物の製造方法及び免疫賦活剤
KR102351363B1 (ko) 수용화 매스틱 검 또는 감태나무 추출물을 이용한 항알러지용 조성물
JP7104169B2 (ja) 腎臓疾患進行抑制及び予防用プロバイオティクス及びこれを含む腎臓疾患進行抑制及び予防用組成物
WO2009093533A1 (fr) INHIBITEUR DE LA PRODUCTION D'ANTICORPS IgE
KR100828069B1 (ko) 푸코잔틴 또는 이를 함유하는 해조류 추출물을 포함하는,지방간의 예방 또는 치료용 조성물
KR20200046201A (ko) 비피도박테리움 애니멀리스 서브스페시스 락티스 HY8002와 비피도박테리움 아돌레센티스 HY8502의 유산균 조합을 이용한 진세노사이드 Rd가 강화된 발효홍삼 농축액을 유효성분으로 함유하는 알레르기성 비염을 개선하기 위한 조성물
WO2005051405A1 (fr) Promoteurs de production d'il-8 et leur utilisation
JP5506229B2 (ja) メタボリックシンドローム改善又は予防剤
JP2011074062A (ja) 抗ｉ型アレルギー剤
JP7479521B2 (ja) 新規なフィーカリバクテリウムプラウスニッツィイｅｂ－ｆｐｄｋ９菌株およびその用途
JP5548379B2 (ja) 花粉荷を含有する抗ヒスタミン剤
KR101910099B1 (ko) 미성숙 감으로부터 가압 열수 방법으로 추출한 추출물 유효성분으로 포함하는 지질대사 개선 또는 항비만용 조성물
CN114615898A (zh) 利用植物乳杆菌菌株等的呼吸系统疾病改善用组合物
JP2010208965A (ja) Ｌｄｌレセプター合成促進剤
KR20200069077A (ko) 셀러리 가수분해물을 유효성분으로 함유하는 아토피 피부염의 예방, 개선 또는 치료용 조성물
KR102211035B1 (ko) 곤충 추출물을 포함하는 암 치료용 및 개선용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10835891

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2011545188

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10835891

Country of ref document: EP

Kind code of ref document: A1